Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 15Myeloid 12Lymphoid 6Classical hematology 5Plasma cell 2Dermatologic 2Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Cytogenetic Analysis × Plasma cell × Clear all
NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

City of Hope Medical Center

Phase 1/2 Completed
54 enrolled 13 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT00792142 2021-08-19

Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
45 enrolled 8 charts
Plasma cell

Multiple Myeloma, Neurotoxicity Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡